A study of RADA16 for same-day aquablation
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a substance called RADA16 can help men who have a procedure called aquablation for an enlarged prostate (BPH) go home the same day. It aims to make recovery faster and more comfortable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man having aquablation for urinary symptoms caused by an enlarged prostate (BPH).
- You must be willing to sign consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tranexamic acid, a medicine that helps blood clot, reduces bleeding during aquablation surgery for an enlarged prostate. If you are a man scheduled for aquablation, this study may help improve your safety and recovery.
This study tests a robotic system with ultrasound accessories to help people who have bothersome urinary symptoms from an enlarged prostate. It’s mainly looking to see if the treatment can be safely done while you’re able to follow the study plan and procedures.
This trial combines a biopsy (tissue sampling) with a heat-based ablation procedure in one visit to diagnose and treat early prostate cancer while also relieving severe urinary symptoms. It may help patients who need quick treatment and early discharge.
This study collects information on men who have urinary symptoms and are planning a procedure called transperineal laser ablation. The goal is to better understand who gets this treatment and what happens afterward.
This trial tests a new device that uses pulsed electric fields to shrink an enlarged prostate (benign prostatic hyperplasia, or BPH). It's for men who have tried medication but still have bothersome symptoms.
This study compares two minimally invasive heat-based treatments for enlarged prostate glands that are causing urinary symptoms. Both treatments target the middle lobe of the prostate, which often causes the most obstruction.
Hear when a new Hematuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.